For research and educational purposes only. Not intended for human consumption.
Adipotide
Limited Research- •Primate fat loss data (11% body weight)
- •Development halted - kidney safety signals
- •Prohibitin/annexin A2 targeting mechanism
Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity
Overview
What is Adipotide?
Adipotide (Prohibitin-TP01) is a chimeric peptidomimetic that homes to prohibitin/annexin A2 on white adipose tissue endothelium and delivers a pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, but development halted after early Phase 1 oncology trial due to kidney safety signals.
Key Benefits
Rapid fat-mass reduction in obese primates with improved insulin sensitivity, direct WAT vascular targeting.
Mechanism of Action
CKGGRAKDC homes to prohibitin/annexin A2 on white-fat endothelium; the linked D-(KLAKLAK)2 disrupts mitochondrial membranes after internalization, triggering localized endothelial apoptosis and adipocyte loss.
Molecular Information
Pharmacokinetics
Research Indications
Adipose Mass Reduction
Selective WAT vascular targeting produced 7-15% body-weight loss over 4 weeks in obese macaques.
Research Protocols
Disclaimer: CRITICAL: Adipotide development was halted due to kidney safety signals. This compound is NOT recommended for human use. Research only.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Primate Research Replication | 0.43 mg/kg | Once daily | Subcutaneous |
| Dose-Finding (Research) | 0.10-0.75 mg/kg | Once daily (escalating) | Subcutaneous |
Timing: Rotate SC sites to reduce irritation; ensure adequate hydration and frequent renal labs during any research use.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Sanitize hands and workspace; swab vial septum
Inject BAC water slowly down the vial wall
Gently swirl until fully dissolved (do not shake)
Label with concentration/date; store at 2-8°C
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Development Halted
Adipotide was discontinued due to kidney safety signals in Phase 1.
Renal Toxicity Risk
Dose-dependent, largely reversible proximal tubule changes observed in primates.
Clear solution
Fully dissolved, particle-free solution after reconstitution.
Collapsed/moist cake
Suggests temperature excursion; do not use.
What to Expect
- •Week 1-2: Early reduction in abdominal circumference
- •Week 2-4: Progressive weight/fat-mass decline
- •Recovery: Partial rebound possible after discontinuation
- •Common lab signals: Mild creatinine rise, electrolyte shifts
Side Effects & Safety
Side Effects
- •Not FDA-approved; investigational/educational only
- •CRITICAL: Monitor serum creatinine, BUN, urinalysis, electrolytes weekly
- •Kidney: Dose-dependent, largely reversible proximal tubule changes in primates
- •Avoid dehydration; pause if creatinine rises persistently
- •Development was HALTED due to safety concerns
When to Stop
- •Any creatinine elevation
- •Signs of kidney stress
- •Electrolyte abnormalities
- •Immediately if any adverse effects
References
2 StudiesObese Rhesus Macaques (2011)
Macaques | 0.43 mg/kg SC daily | 28 days | 7.4-14.7% weight loss; reversible renal changes
White-adipose vasculature targeting led to rapid fat mass reduction. Kidney signals were dose-related and largely reversible.
Dose-Finding Study (2011)
Macaques | 0.10-0.75 mg/kg SC | 63 days | Optimal dose 0.43 mg/kg
Identified optimal dosing balancing efficacy and renal safety.
Quick Start Guide
Research Disclaimer
Adipotide is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Adipotide must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Adipotide for any purpose. Consult qualified professionals for any research applications.